GoodRx and Eli Lilly partner to expand acess to oral weight loss medication Foundayo at $149 monthly
GoodRx (NASDAQ:GDRX), the leading U.S. prescription savings platform, announced on April 9, 2026, a strategic collaboration with Eli Lilly and Company to improve affordability for the newly launched oral GLP-1 medication, Foundayo™ (orforglipron).










